Home / Current Issue / Paper 1718802
Formulation and Evaluation of Danazol Tablets Using Cyclodextrin Complexation for Improved Oral Bioavailability
Subject area: Science,Engineering and Technology · Area of research: Pharmacy
DOI: 10.64388/IREV9I12-1718802
Abstract
Danazol, a BCS Class II synthetic isoxazole derivative of 17α-ethinyl testosterone, exhibits extremely poor aqueous solubility (< 1 μg/mL) and characteristically low, highly variable oral bioavailability (2–6%) from conventional formulations, necessitating high daily doses of 200–800 mg and predisposing patients to dose-dependent androgenic adverse effects. This study investigated cyclodextrin inclusion complexation as a solubility and dissolution enhancement strategy for danazol tablet development. Danazol–cyclodextrin inclusion complexes were prepared using β-cyclodextrin (β-CD) and hydroxypropyl-β-cyclodextrin (HP-β-CD) at drug-to-cyclodextrin molar ratios of 1:1 and 1:2 by three methods: physical mixing, kneading, and solvent evaporation, yielding eight formulations (F1–F8). Complexes were characterized by Fourier Transform Infrared spectroscopy (FT-IR), Differential Scanning Calorimetry (DSC), and Powder X-Ray Diffraction (PXRD). Phase solubility studies were conducted following the Higuchi–Connors method. Tablet formulations (T1–T6) were prepared by direct compression and evaluated for pharmacopoeial quality attributes and in-vitro dissolution performance. Phase solubility studies confirmed AL-type profiles for both cyclodextrins, with HP-β-CD demonstrating superior stability constants (Ks = 2847.3 M⁻¹ vs 685.4 M⁻¹ for β-CD) and 22.3-fold solubility enhancement at 10 mM. FT-IR, DSC, and PXRD analyses converged in identifying F8 (danazol:HP-β-CD, 1:2, solvent evaporation) as the optimally amorphized complex, exhibiting complete loss of danazol crystallinity. The optimized tablet T6 achieved 93.8% drug dissolution within 90 minutes — a 5.9-fold improvement over pure danazol control (16.8%) — with T50% reduced from >90 to 10.4 minutes (87% reduction). All tablet formulations met pharmacopoeial quality specifications. Drug release followed Fickian diffusion (Korsmeyer–Peppas R² = 0.9882, n = 0.428). Cyclodextrin inclusion complexation, particularly with HP-β-CD via solvent evaporation, represents a scientifically validated, pharmaceutically viable, and industrially scalable strategy for dramatically improving danazol oral bioavailability. The direct compression tablet manufacturing approach further enhances commercial feasibility.
Keywords
Danazol, Cyclodextrin inclusion complex, β-Cyclodextrin, Hydroxypropyl-β-cyclodextrin, BCS Class II, Solubility enhancement, Oral bioavailability, Direct compression, In-vitro dissolution
References
[1] Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995). A theoretical basis for a biopharmaceutics drug classification. Pharmaceutical Research, 12(3), 413–420.
[2] Brewster, M. E., & Loftsson, T. (2007). Cyclodextrins as pharmaceutical solubilizers. Advanced Drug Delivery Reviews, 59(7), 645–666.
[3] Carrier, R. L., Miller, L. A., & Ahmed, I. (2007). The utility of cyclodextrins for enhancing oral bioavailability. Journal of Controlled Release, 123(2), 78–99.
[4] Challa, R., Ahuja, A., Ali, J., & Khar, R. K. (2005). Cyclodextrins in drug delivery: An updated review. AAPS PharmSciTech, 6(2), E329–E357.
[5] Childs, S. L., Kandi, P., & Lingireddy, S. R. (2013). Formulation of a danazol cocrystal with controlled supersaturation. Molecular Pharmaceutics, 10(8), 3112–3127.
[6] Dressman, J. B., Reppas, C., & Vertzoni, M. (2007). In vitro–in vivo correlations and gastrointestinal dissolution behavior. European Journal of Pharmaceutical Sciences, 31(2), 84–89.
[7] Frömming, K. H., & Szejtli, J. (1994). Cyclodextrins in Pharmacy. Kluwer Academic Publishers.
[8] Higuchi, T., & Connors, K. A. (1965). Phase-solubility techniques. Advances in Analytical Chemistry and Instrumentation, 4, 117–212.
[9] Jain, S., Patel, N., & Lin, S. (2010). Solubility and dissolution enhancement using cyclodextrins. Drug Development and Industrial Pharmacy, 37(2), 16–22.
[10] Korsmeyer, R. W., Gurny, R., Doelker, E., Buri, P., & Peppas, N. A. (1983). Mechanisms of solute release from porous hydrophilic polymers. International Journal of Pharmaceutics, 15(1), 25–35.
[11] Loftsson, T., Brewster, M. E., & Másson, M. (2004). Role of cyclodextrins in improving oral drug delivery. American Journal of Drug Delivery, 2(4), 261–275.
[12] Mura, P., Bettinetti, G. P., Cirri, M., & Faucci, M. T. (2001). Solid-state properties of drug–cyclodextrin complexes. Journal of Pharmaceutical Sciences, 90(4), 465–477.
[13] Patel, R. P., Patel, M. M., & Patel, D. J. (2008). Cyclodextrin inclusion complexes for solubility enhancement. Drug Development and Industrial Pharmacy, 34(3), 267–275.
[14] Savolainen, J., Jarvinen, K., & Jarho, P. (1998). Improved dissolution and bioavailability of steroids using cyclodextrins. International Journal of Pharmaceutics, 170(1), 1–10.
[15] Sharma, A., Jain, C. P., & Tanwar, Y. S. (2015). Preparation and evaluation of CD complexes. Journal of Drug Delivery Science and Technology, 30, 230–238.
[16] Sweetman, S. C. (Ed.). (2011). Martindale: The Complete Drug Reference (37th ed.). Pharmaceutical Press.
[17] Szejtli, J. (2004). Past, present and future of cyclodextrin research. Pure and Applied Chemistry, 76(10), 1825–1845.
[18] Uekama, K., Hirayama, F., & Irie, T. (1998). Cyclodextrin drug carrier systems. Chemical Reviews, 98(5), 2045–2076.
[19] Yalkowsky, S. H., He, Y., & Jain, P. (2004). Handbook of Aqueous Solubility Data. CRC Press.
How to cite this paper
@article{1718802,
author = {Surabhi Kumari, Vishal Kumar Singh},
title = {Formulation and Evaluation of Danazol Tablets Using Cyclodextrin Complexation for Improved Oral Bioavailability},
journal = {Iconic Research And Engineering Journals},
year = {2026},
volume = {9},
number = {12},
pages = {970-978},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1718802.pdf},
abstract = {Danazol, a BCS Class II synthetic isoxazole derivative of 17α-ethinyl testosterone, exhibits extremely poor aqueous solubility (< 1 μg/mL) and characteristically low, highly variable oral bioavailability (2–6%) from conventional formulations, necessitating high daily doses of 200–800 mg and predisposing patients to dose-dependent androgenic adverse effects. This study investigated cyclodextrin inclusion complexation as a solubility and dissolution enhancement strategy for danazol tablet development.
Danazol–cyclodextrin inclusion complexes were prepared using β-cyclodextrin (β-CD) and hydroxypropyl-β-cyclodextrin (HP-β-CD) at drug-to-cyclodextrin molar ratios of 1:1 and 1:2 by three methods: physical mixing, kneading, and solvent evaporation, yielding eight formulations (F1–F8). Complexes were characterized by Fourier Transform Infrared spectroscopy (FT-IR), Differential Scanning Calorimetry (DSC), and Powder X-Ray Diffraction (PXRD). Phase solubility studies were conducted following the Higuchi–Connors method. Tablet formulations (T1–T6) were prepared by direct compression and evaluated for pharmacopoeial quality attributes and in-vitro dissolution performance.
Phase solubility studies confirmed AL-type profiles for both cyclodextrins, with HP-β-CD demonstrating superior stability constants (Ks = 2847.3 M⁻¹ vs 685.4 M⁻¹ for β-CD) and 22.3-fold solubility enhancement at 10 mM. FT-IR, DSC, and PXRD analyses converged in identifying F8 (danazol:HP-β-CD, 1:2, solvent evaporation) as the optimally amorphized complex, exhibiting complete loss of danazol crystallinity. The optimized tablet T6 achieved 93.8% drug dissolution within 90 minutes — a 5.9-fold improvement over pure danazol control (16.8%) — with T50% reduced from >90 to 10.4 minutes (87% reduction). All tablet formulations met pharmacopoeial quality specifications. Drug release followed Fickian diffusion (Korsmeyer–Peppas R² = 0.9882, n = 0.428).
Cyclodextrin inclusion complexation, particularly with HP-β-CD via solvent evaporation, represents a scientifically validated, pharmaceutically viable, and industrially scalable strategy for dramatically improving danazol oral bioavailability. The direct compression tablet manufacturing approach further enhances commercial feasibility.},
keywords = {Danazol, Cyclodextrin inclusion complex, β-Cyclodextrin, Hydroxypropyl-β-cyclodextrin, BCS Class II, Solubility enhancement, Oral bioavailability, Direct compression, In-vitro dissolution},
month = {June},
doi = {https://doi.org/10.64388/IREV9I12-1718802}
}